LONDON, Aug. 29,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
("Virax" or the "Company") (Nasdaq: VRAX), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, announced today it will be hosting
a booth at the 7th European Congress of Immunology
(ECI), which is taking place from September
1 - 4, 2024, in Dublin,
Ireland.
The Company will be showcasing its portfolio of immune profiling
products for research use at Booth C13, and management will be
available for discussions with research organizations and potential
customers.
The European Congress of Immunology is the triennial joint
meeting of all European Federation of Immunological Societies
(EFIS). It is now one of the most highly regarded international
conferences in the field of basic and clinical immunology,
attracting on average more than 3,000 delegates and offering the
highest standards in terms of both scientific and social programs.
The theme for this year's congress is 'Conquering challenges with
Immunology'.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-viral syndromes such as Long COVID and other
chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners,
LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-to-participate-at-7th-european-congress-of-immunology-302234080.html
SOURCE Virax Biolabs